Shortage of injectable enalaprilat

The American Society of Health-System Pharmacists reports a shortage of injectable enalaprilat. This drug shortage is yet another that arises from the voluntary closure of Ben Venue's manufacturing facility, where injectable enalaprilat was produced under contract for Bedford Laboratories. There is no mention of why Hospira's product is in short supply. This drug will injure and possibly kill a developing fetus. When medication cannot be taken by mouth, this is an injectable option for control of high blood pressure. It is an angiotension I-converting-enzyme inhibitor (ACEI).